Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Apr 2023
The treatment of chronic thromboembolic pulmonary hypertension with balloon pulmonary angioplasty has an evolving safety profile over the years, from 2013 to 2022, as revealed by an analysis of more than two dozen studies.
Read Full NewsA viral plastic diet trend raises concerns for choking, metabolic disruption, and increased risk for eating disorders among youth.
Higher intensity of physical activity, regardless of total volume, is linked to significantly lower risks for many cardiovascular and other chronic diseases and death.
1.
Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?
2.
Effects of Recombinant Replacement Therapy Explained in Detailed Regarding Genetic Clotting Disorder.
3.
Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.
4.
Next Day Mood Is Affected by Ability to Recover From Work.
5.
GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.
1.
Advancements in Breast Cancer Treatment: From Chemotherapy to Immunotherapy
2.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
3.
Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer
4.
Neutrophil Profiling and AI Rewrites Cancer Diagnosis
5.
Case Study: Personalized Medicine Based on Genetic Profiling in Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
4.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
5.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge